Vivek Patel
Hematology & Oncology · Nashville, TNNPI 1740716158
Payments from drug & device makers
Across 37 payments — averaging $406.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab U.S., Inc.$8K
- Acrotech Biopharma Inc.$4K
- Ipsen Biopharmaceuticals, Inc$2K
- Beigene USA, Inc.$675
- Spark Therapeutics, Inc.$443
- Regeneron$215
- plus $17 from 1 others
What the payments were for
- Consulting fees$5,15534%
- Speaking & faculty fees$5,69538%
- Travel & lodging$3,30722%
- Food & beverage$8986%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab U.S., Inc. | 16 | $7,977 |
| Acrotech Biopharma Inc. | 4 | $3,658 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,070 |
| Beigene USA, Inc. | 1 | $675 |
| Spark Therapeutics, Inc. | 11 | $443 |
| Regeneron | 3 | $215 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,055 in reported general payments places this provider in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 23 | $336,461 |
| VenclextaVenetoclax | 15 | $234,678 |
| ValacyclovirValacyclovir Hcl | 33 | $1,632 |
| Mercaptopurine | 11 | $1,089 |
| MethotrexateMethotrexate Sodium | 13 | $576 |
| Ondansetron Hcl | 12 | $521 |
| Prednisone | 22 | $81 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Nashville
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
- Krish PatelNashville$14.2M
- Denise YardleyNashville$13.2M
- Todd BauerNashville$10.9M
- Wade IamsNashville$8.9M
- Benjamin GarmezyNashville$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.